However , carnitine supplementation at dosages of ≤ 1000 mg/day ( p = 0.035 ) or equal to 2000 mg/day ( p = 0.013 ) result ed in significant reduction in ALT level , while doses more than 2000 mg/day did not change ALT  significantly .
Carnitine exerts its reducing effect on serum ALT and AST levels only when these aminotransferases are raised or when the duration of supplementation lasts at least 3 months .
Results of the current meta- analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly , especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels
Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
Background / Aims Carnitine and vitamin complex ( Godex ® ) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea . The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase ( ALT ) elevated Chronic Hepatitis B ( CHB ) patients . Methods 130 treatment-naïve patients with CHB were enrolled from 13 sites . The patients were r and omly selected to the entecavir and the complex of entecavir and carnitine . The primary endpoint of the study is ALT normalization level after 12 months . Results Among the 130 patients , 119 patients completed the study treatment . The ALT normalization at 3 months was 58.9 % for the monotherapy and 95.2 % for the combination therapy ( P<0.0001 ) . ALT normalization rate at 12 months was 85.7 % for the monotherapy and 100 % for the combination group ( P=0.0019 ) . The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant ( P=0.5318 ) 75.9 % for the monotherapy , 70.7 % for the combination and it was . Quantification of HBsAg level was not different from the monotherapy to combination at 12 months . Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment . Conclusions ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB . Combination group was faster than entecavir mono-treatment group on ALT normalization rate . HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment
However , carnitine supplementation at dosages of ≤ 1000 mg/day ( p = 0.035 ) or equal to 2000 mg/day ( p = 0.013 ) result ed in significant reduction in ALT level , while doses more than 2000 mg/day did not change ALT  significantly .
Carnitine exerts its reducing effect on serum ALT and AST levels only when these aminotransferases are raised or when the duration of supplementation lasts at least 3 months .
Results of the current meta- analysis showed that carnitine supplementation can decrease serum AST and ALT levels significantly , especially when supplementation lasts 3 months or more in patients with elevated serum aminotransferase levels